ArticleDiscover oncology2026
PSMC2 drives tumor progression in nasopharyngeal carcinoma by inhibiting ferroptosis through STAT3.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNasopharyngeal carcinoma (NPC) mortality is driven primarily by malignant proliferation and metastasis. Although PSMC2 contributes to tumor progression, its mechanistic role in NPC pathogenesis remains undefined.
methodsProtein expression levels were detected via WB and immunohistochemistry. Cell activity was measured by a CCK8 assay. The cell migration ability was detected via wound-healing assays. Cell death was detected by flow cytometry. The levels of ROS, lipid peroxidation and iron ions were observed via confocal microscopy. The level of GSH was detected with a microplate reader. The growth abilities of the tumors were analyzed with a subcutaneous tumor model.
resultsPSMC2 is highly expressed in NPC. Compared with those in the control group, cell proliferation activity and migration ability were decreased, the phosphorylation level of STAT3 was decreased, the protein expression of CPT1 and GPX4 was downregulated, ROS and lipid peroxidation levels were increased, GSH levels were significantly decreased, iron ion levels were significantly increased, and ferroptosis levels were increased in the PSMC2 knockdown group. Compared with those in the PSMC2-knockdown group, the cell proliferation activity and migration ability were increased, the phosphorylation level of STAT3 was increased, the protein expression of CPT1 and GPX4 was increased, the ROS and lipid peroxidation levels were decreased, the GSH levels were significantly increased, the iron ion levels were significantly decreased, and the cell activity was increased. Tumor growth was significantly reduced with PSMC2 knockdown.
conclusionsPSMC2 upregulates CPT1 and GPX4 by activating STAT3, inhibits ferroptosis induced by lipid peroxidation, and drives malignant proliferation and metastasis in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.